Search Results | Blood | American Society of Hematology

1-20 of 85

2 3 4 5

Sort by

Sort Order Select

Journal Articles

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

Eun-Ju Lee, Marina Beltrami-Moreira, Hanny Al-Samkari, Adam Cuker, Jennifer DiRaimo, Terry Gernsheimer, Alexandra Kruse, Craig Kessler, Caroline Kruse, Andrew D. Leavitt, Alfred I. Lee, Howard A. Liebman, Adrian C. Newland, Ashley E. Ray, Michael D. Tarantino, Jecko Thachil, David J. Kuter, Douglas B. Cines, James B. Bussel

Blood (2022) 139 (10): 1564–1574.

DOI: https://doi.org/10.1182/blood.2021013411

Published: 2022

Includes: Supplemental data

Journal Articles

Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study)

Galina Tsykunova, Pal André Holme, Hoa Thi Tuyet Tran, Tor Henrik Anderson Tvedt, Ludvig Andre Munthe, Marc Michel, Henrik Frederiksen, James B Bussel, David J. Kuter, Waleed Ghanima

Blood (2021) 138 (Supplement 1): 2088.

DOI: https://doi.org/10.1182/blood-2021-151410

Published: 2021

Journal Articles

Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia

Blood (2021) 138 (Supplement 1): 14.

DOI: https://doi.org/10.1182/blood-2021-145128

Published: 2021

Journal Articles

Thrombopoietin Level Predicts Response to Treatment with Romiplostim in Chemotherapy-Induced Thrombocytopenia

Andrew B Song, Katayoon Goodarzi, Rebecca Karp Leaf, David J. Kuter, Hanny Al-Samkari

Blood (2021) 138 (Supplement 1): 584.

DOI: https://doi.org/10.1182/blood-2021-145931

Published: 2021

Journal Articles

Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia

Eun-Ju Lee, Marina Beltrami Moreira, Hanny Al-Samkari, Adam Cuker, Jennifer MacWhirter - DiRaimo, Terry B. Gernsheimer, Alexandra Kruse, Craig M. Kessler, Caroline Kruse, Andrew D Leavitt, Alfred Ian Lee, Howard A. Liebman, Adrian C. Newland, Ashley E. Ray, Michael D Tarantino, Jecko Thachil, David J. Kuter, Douglas B. Cines, James B Bussel

Blood (2021) 138 (Supplement 1): 586.

DOI: https://doi.org/10.1182/blood-2021-152918

Published: 2021

Journal Articles

LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia

David J. Kuter, James B Bussel, Nichola Cooper, Terry Gernsheimer, Michele P. Lambert, Howard Liebman, Michael D Tarantino, Olga Bandman, Puneet Arora, Ann Neale, Regan Burns, Mengjie Yao, Waleed Ghanima

Blood (2021) 138 (Supplement 1): 1010.

DOI: https://doi.org/10.1182/blood-2021-144504

Published: 2021

Journal Articles

How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment

Waleed Ghanima, Terry Gernsheimer, David J. Kuter

Blood (2021) 137 (20): 2736–2744.

DOI: https://doi.org/10.1182/blood.2021010968

Published: 2021

Journal Articles

Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress

Adrian C. Newland, Howard A. Liebman, MD, Vickie McDonald, MD, Marc Michel, Yoshitaka Miyakawa, Wim Parys, MD, Hans De Haard, Peter Ulrichts, Marie Godar, Kristof De Beuf, Jaume Ayguasanosa, Catherine M Broome, David J. Kuter, MD

Blood (2020) 136 (Supplement 1): 6–7.

DOI: https://doi.org/10.1182/blood-2020-141161

Published: 2020

Journal Articles

Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia

David J. Kuter, MD, Merlin Efraim, MD, Jiri Mayer, MD, Vickie McDonald, MD, Robert J. Bird, FRACP,FRCP,FRCPA,MBBS,MRCP, Thomas Regenbogen, MD, Mamta Garg, MD FRCP, FRCPath, Zane Kaplan, MBBS(Hons) BMedSc(Hons) PhDFRACP FRCPA, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP

Blood (2020) 136 (Supplement 1): 13–14.

DOI: https://doi.org/10.1182/blood-2020-134932

Published: 2020

Journal Articles

Eighteen-Month Interim Analysis of Efficacy and Safety of Givosiran, an RNAi Therapeutic for Acute Hepatic Porphyria, in the Envision Open Label Extension

David J. Kuter, MD, Sioban Keel, MD, Charles J. Parker, MD, David C. Rees, MD, Ulrich Stölzel, MD, Paolo Ventura, MD, Manisha Balwani, Laurent Gouya, MD, PhD, Amy Simon, MD, Shangbin Liu, PhD, John J Ko, PharmD,MSc, Sean Rhyee, MD, M.P.H, Samuel M. Silver, MD PhD

Blood (2020) 136 (Supplement 1): 13.

DOI: https://doi.org/10.1182/blood-2020-134564

Published: 2020

Journal Articles

Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia

Catherine M. Broome, Alexander Röth, MD, David J. Kuter, MD, Marie Scully, MD, Roy Smith, Jennifer Wang, Xiaoyu Jiang, Caroline Reuter, Ahmed Daak, William Hobbs

Blood (2020) 136 (Supplement 1): 14–15.

DOI: https://doi.org/10.1182/blood-2020-139663

Published: 2020

Journal Articles

Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19

Hanny Al-Samkari, MD, Fei Song, MD, Elizabeth M. Van Cott, MD, David J. Kuter, MD, Rachel P. Rosovsky, MD MPH

Blood (2020) 136 (Supplement 1): 4–5.

DOI: https://doi.org/10.1182/blood-2020-134605

Published: 2020

Journal Articles

Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study

Nichola Cooper, MD, Robert P. Numerof, PhD, Sandra Tong, MD, David J. Kuter, MD

Blood (2020) 136 (Supplement 1): 1–3.

DOI: https://doi.org/10.1182/blood-2020-140469

Published: 2020

Journal Articles

Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders and Tendencies: Methodology for Delphi Consensus Recommendations

Wynn Peterson, MD, Rachel Martin, MD, Brendan Carvalho, MD, Jose Carvalho, MD, Jeff Gadsden, MD, Peter A. Kouides, MD, David J. Kuter, MD, Michelle Lavin, MB, PhD FRCPath, Natalia Rydz, Eliane Shore, MDMSc FRCSC, Michelle Sholzberg, MDM, FRCPC, MSc

Blood (2020) 136 (Supplement 1): 29.

DOI: https://doi.org/10.1182/blood-2020-138837

Published: 2020

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up

Alexander Röth, MD, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, MD, Bernd Jilma, Tor Henrik Anderson Tvedt, Ilene C. Weitz, Parija Patel, Xiaoyu Jiang, Caroline Reuter, Jun Su, Frank Shafer, Michelle Lee, William Hobbs, Sigbjørn Berentsen

Blood (2020) 136 (Supplement 1): 24–25.

DOI: https://doi.org/10.1182/blood-2020-138909

Published: 2020

Journal Articles

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

Hanny Al-Samkari, Rebecca S. Karp Leaf, Walter H. Dzik, Jonathan C. T. Carlson, Annemarie E. Fogerty, Anem Waheed, Katayoon Goodarzi, Pavan K. Bendapudi, Larissa Bornikova, Shruti Gupta, David E. Leaf, David J. Kuter, Rachel P. Rosovsky

Blood (2020) 136 (4): 489–500.

DOI: https://doi.org/10.1182/blood.2020006520

Published: 2020

Includes: Supplemental data

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Alexander Röth, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, Bernd Jilma, Tor Henrik Anderson Tvedt, Stella Lin, Xiaoyu Jiang, Caroline Reuter, William Hobbs, Sigbjørn Berentsen

Blood (2019) 134 (Supplement_2): LBA-2.

DOI: https://doi.org/10.1182/blood-2019-132490

Published: 2019

Journal Articles

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

Kerry A. Rogers, MD, Michael A. Boxer, MD, Michael Y. Choi, MD, Richy Agajanian, MD, Donald M. Arnold, MD, Catherine M. Broome, MD, Joshua J. Field, MD, Irina Murakhovskaya, MD, Donna Chow, Robert P. Numerof, PhD, Hanzhe Zheng, PhD, Sandy Tong, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 3518.

DOI: https://doi.org/10.1182/blood-2019-126509

Published: 2019

Journal Articles

Characterization of the Rate, Predictors, and Thrombotic Complications of Thrombocytosis in Iron Deficiency Anemia

Andrew B Song, BA, David J. Kuter, Hanny Al-Samkari, MD

Blood (2019) 134 (Supplement_1): 959.

DOI: https://doi.org/10.1182/blood-2019-122359

Published: 2019

Journal Articles

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Adrian C. Newland, Blanca Sánchez-González, László Rejtő, Miklos Egyed, Nataliya Romanyuk, Marie Godar, Katrien Verschueren, Domenica Gandini, Peter Ulrichts, Jon Beauchamp, Torsten Dreier, E. Sally Ward, Marc Michel, Howard A. Liebman, Hans De Haard, Nicolas Leupin, David J. Kuter

Blood (2019) 134 (Supplement_1): 895.

DOI: https://doi.org/10.1182/blood-2019-128022

Published: 2019

2 3 4 5

NARROW

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study)

Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia

Thrombopoietin Level Predicts Response to Treatment with Romiplostim in Chemotherapy-Induced Thrombocytopenia

Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia

LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia

How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment

Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress

Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia

Eighteen-Month Interim Analysis of Efficacy and Safety of Givosiran, an RNAi Therapeutic for Acute Hepatic Porphyria, in the Envision Open Label Extension

Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia

Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19

Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study

Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders and Tendencies: Methodology for Delphi Consensus Recommendations

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

Characterization of the Rate, Predictors, and Thrombotic Complications of Thrombocytosis in Iron Deficiency Anemia

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only